Samarawardana Panduka, Singh Meenakshi, Shroyer Kenneth R
Department of Pathology, Stony Brook University Medical Center, Stony Brook, NY 11794-8691, USA.
Appl Immunohistochem Mol Morphol. 2011 Dec;19(6):514-8. doi: 10.1097/PAI.0b013e3182167c66.
The primary goal of this study was to assess the clinical utility of a multiplexed immunohistochemical method using colocalization of p16 and Ki-67 in identifying high-grade cervical mucosal lesions.
The study included formalin-fixed cervical biopsy specimens, representative of 297 diagnostic regions. They were subjected to 2 colors immunohistochemical staining for p16 and Ki-67 using an EnVision polymer-based method. The chromogens used were of DAB brown for the detection of p16 and alkaline phosphatase blue for Ki-67. Histologic regions were scored positive for either marker based on the detection of p16 or Ki-67 in >10% of the cells of interest.
Positive test results with colocalization of p16/Ki-67 were found in 20 of 40 cases of cervical intraepithelial neoplasia 1 (n=40) and in all cases of cervical intraepithelial neoplasia 2/3 (n=32), squamous cell carcinoma (n=11), adenocarcinoma in situ (n=10), and invasive adenocarcinoma (n=8). Colocalization of p16/Ki-67 was also detected in few cells in 1 of 19 sections with tuboendometrial metaplasia but was not detected in normal squamous mucosa (n=78), normal endocervical mucosa (n=76), immature squamous metaplasia (n=13), or in microglandular hyperplasia (n=9).
The p16 and Ki-67 are coexpressed in virtually 100% of cases of high-grade squamous and glandular lesions, but they are rarely coexpressed in normal tissues or in benign lesions of the squamous and glandular mucosa. Thus, multiplexed colocalization of p16 and Ki-67 is a practical and potentially powerful diagnostic approach to enhance the accuracy of cervical histopathologic diagnosis.
本研究的主要目的是评估使用p16和Ki-67共定位的多重免疫组织化学方法在识别高级别宫颈黏膜病变中的临床实用性。
该研究纳入了代表297个诊断区域的福尔马林固定宫颈活检标本。使用基于EnVision聚合物的方法对它们进行p16和Ki-67的双色免疫组织化学染色。所使用的显色剂为用于检测p16的DAB棕色和用于Ki-67的碱性磷酸酶蓝色。根据在>10%的目标细胞中检测到p16或Ki-67,将组织学区域对任一标记物评分为阳性。
在40例宫颈上皮内瘤变1级(n = 40)中的20例以及所有宫颈上皮内瘤变2/3级(n = 32)、鳞状细胞癌(n = 11)、原位腺癌(n = 10)和浸润性腺癌(n = 8)病例中发现p16/Ki-67共定位的阳性检测结果。在19例伴有输卵管子宫内膜化生的切片中的1例的少数细胞中也检测到p16/Ki-67共定位,但在正常鳞状黏膜(n = 78)、正常宫颈内膜黏膜(n = 76)、未成熟鳞状化生(n = 13)或微腺性增生(n = 9)中未检测到。
p16和Ki-67在几乎100%的高级别鳞状和腺性病变病例中共表达,但在正常组织或鳞状和腺性黏膜的良性病变中很少共表达。因此,p16和Ki-67的多重共定位是一种实用且可能强大的诊断方法,可提高宫颈组织病理学诊断的准确性。